Want to see HKMPY full AI Analyst Report?
Total Valuation
Hikma Pharmaceuticals has a market cap or net worth of $4.62B. The enterprise value is $6.09K.
Market Cap$4.62B
Enterprise Value$6.09K
Share Statistics
Hikma Pharmaceuticals has 104,786,350 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding104,786,350
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Hikma Pharmaceuticals’s return on equity (ROE) is 0.16 and return on invested capital (ROIC) is 10.31%.
Return on Equity (ROE)0.16
Return on Assets (ROA)0.07
Return on Invested Capital (ROIC)10.31%
Return on Capital Employed (ROCE)0.13
Revenue Per Employee357.11K
Profits Per Employee42.87K
Employee Count9,400
Asset Turnover0.59
Inventory Turnover1.73
Valuation Ratios
The current PE Ratio of Hikma Pharmaceuticals is 12.4. Hikma Pharmaceuticals’s PEG ratio is 0.88.
PE Ratio12.4
PS Ratio1.38
PB Ratio1.78
Price to Fair Value1.78
Price to FCF28.48
Price to Operating Cash Flow11.84
PEG Ratio0.88
Income Statement
In the last 12 months, Hikma Pharmaceuticals had revenue of 3.36B and earned 402.94M in profits. Earnings per share was 3.66.
Revenue3.36B
Gross Profit1.44B
Operating Income569.33M
Pretax Income520.21M
Net Income402.94M
EBITDA781.82M
Earnings Per Share (EPS)3.66
Cash Flow
In the last 12 months, operating cash flow was 398.53M and capital expenditures -249.65M, giving a free cash flow of 148.88M billion.
Operating Cash Flow398.53M
Free Cash Flow148.88M
Free Cash Flow per Share1.42
Dividends & Yields
Hikma Pharmaceuticals pays an annual dividend of $0.76, resulting in a dividend yield of 3.7%
Dividend Per Share$0.76
Dividend Yield3.7%
Payout Ratio45.99%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.51
52-Week Price Change-4.45%
50-Day Moving Average41.44
200-Day Moving Average39.49
Relative Strength Index (RSI)59.71
Average Volume (3m)576.00
Important Dates
Hikma Pharmaceuticals upcoming earnings date is Feb 25, 2027, TBA (Confirmed).
Last Earnings DateAug 6, 2026
Next Earnings DateFeb 25, 2027
Ex-Dividend Date―
Financial Position
Hikma Pharmaceuticals as a current ratio of 1.82, with Debt / Equity ratio of 77.57%
Current Ratio1.82
Quick Ratio1.06
Debt to Market Cap0.34
Net Debt to EBITDA1.63
Interest Coverage Ratio5.36
Taxes
In the past 12 months, Hikma Pharmaceuticals has paid 112.26M in taxes.
Income Tax112.26M
Effective Tax Rate0.22
Enterprise Valuation
Hikma Pharmaceuticals EV to EBITDA ratio is 7.55, with an EV/FCF ratio of 36.34.
EV to Sales1.76
EV to EBITDA7.55
EV to Free Cash Flow36.34
EV to Operating Cash Flow16.40
Balance Sheet
Hikma Pharmaceuticals has $289.00M in cash and marketable securities with $1.96B in debt, giving a net cash position of -$1.67B billion.
Cash & Marketable Securities$289.00M
Total Debt$1.96B
Net Cash-$1.67B
Net Cash Per Share-$15.92
Tangible Book Value Per Share$13.02
Margins
Gross margin is 40.88%, with operating margin of 16.96%, and net profit margin of 12.00%.
Gross Margin40.88%
Operating Margin16.96%
Pretax Margin15.50%
Net Profit Margin12.00%
EBITDA Margin23.29%
EBIT Margin16.96%
Analyst Forecast
The average price target for Hikma Pharmaceuticals is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast5.61%
EPS Growth Forecast6.41%